{"nctId":"NCT01856712","briefTitle":"Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence","startDateStruct":{"date":"2013-05"},"conditions":["Alcohol Dependence"],"count":54,"armGroups":[{"label":"oral naltrexone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Naltrexone"]},{"label":"injectable naltrexone","type":"EXPERIMENTAL","interventionNames":["Drug: Naltrexone"]}],"interventions":[{"name":"Naltrexone","otherNames":["Revia, Vivitrol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years or older\n* diagnostic criteria for alcohol dependence or abuse\n* women of childbearing potential who have a negative screening urine pregnancy test and are willing to use reliable birth control methods throughout the duration of the study\n\nExclusion Criteria:\n\n* active or recently active (less than 1 year) opioid dependence or daily use of opioid analgesics\n* acute hepatitis or liver failure\n* pregnancy\n* women who are currently breastfeeding\n* active suicidality\n* inability to provide written informed consent as determined by study comprehension questions","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Retention Rate: Percentage of Participants Attended an Initial Behavioral Treatment Visit Within 2 Weeks of Hospital Discharge.","description":"Retention rate was measured in terms of percentage of participants attended an initial behavioral treatment visit within 2 weeks of hospital discharge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Attended Recommended Outpatient Substance Abuse Treatment","description":"Attendance to recommended outpatient substance abuse treatment will be compared between injectable naltrexone group and oral naltrexone group. Keeping patients engaged in treatment is desirable and is known to improve addiction-related outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Adhered to Medication","description":"Medication adherence was measured as percentage of participants who took â‰¥ 80% of daily naltrexone doses determined via pill counts. Adherence of daily medication will predict treatment engagement following hospital discharge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Ongoing Alcohol Consumption","description":"To compare study arms in terms of ongoing alcohol consumption. We hypothesize that (1) improved medication adherence in the oral naltrexone arm and (2) assignment to injectable naltrexone will be associated with reduced alcohol consumption (number of heavy drinking days in the past 14 days) following hospital discharge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136.5","spread":null},{"groupId":"OG001","value":"114.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["depression"]}}}